Text Size

Bone Marrow Grafting for Leukemia and Lymphoma

This study is currently recruiting participants.
Verified May 2013 by Stanford University
Sponsor:
Collaborators:
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00186147
First received: September 13, 2005
Last updated: May 7, 2013
Last verified: May 2013
History of Changes
  Purpose

Bone Marrow Grafting for Leukemia and Lymphoma


Condition Intervention
Leukemia
Lymphoma
Hematologic Diseases
 Procedure: collection and storage of tissue samples for research

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Bone Marrow Grafting for Leukemia and Lymphoma

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Stanford University:

Biospecimen Retention:   Samples With DNA

Tissue samples will be obtained from subjects undergoing transplantation or donors providing the graft.


Estimated Enrollment: 9999
Study Start Date: March 1988
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Graft recipients and donors Procedure: collection and storage of tissue samples for research
Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.

Detailed Description:

The purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.

  Eligibility

Ages Eligible for Study:   up to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All hematopoietic cell transplant recipients and donors who agree to participate

Criteria

Inclusion Criteria:- All hematopoietic cell transplant recipients and donors who agree to participate

Exclusion Criteria:- Subject does not agree to participate

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00186147

Contacts
Contact: BMT Referrals (650) 723-0822 cctoffice@stanford.edu

Locations
United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: BMT Referrals     650-723-0822     cctoffice@stanford.edu    
Contact: Cancer Clinical Trials Office     (650) 498-7061        
Principal Investigator: David Miklos            
Principal Investigator: Robert S Negrin            
Sub-Investigator: Judith Anne Shizuru            
Sub-Investigator: Laura Johnston            
Sub-Investigator: Sandra Jeane Horning            
Sub-Investigator: Karl G. Blume            
Sponsors and Collaborators
Stanford University
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Investigators
Principal Investigator: David Miklos Stanford University
Principal Investigator: Robert S Negrin Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00186147     History of Changes
Other Study ID Numbers: BMT19, 13358, BMT19
Study First Received: September 13, 2005
Last Updated: May 7, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hematologic Diseases
Leukemia
Lymphoma
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013